RecruitingOBSERVATIONAL

Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas

This study is about making sure French-speaking people who have meningioma brain tumours can properly share how their condition affects their daily lives. Meningiomas are common brain tumours that can have a big impact on how people feel and live, even when they don't need treatment. Currently, there's a good questionnaire called MQOL that helps understand this, but it's not available in French. This project will first translate the MQOL into French. Then, it will be tested with 50 patients who have meningiomas to ensure it’s accurate and reliable. The goal is to better understand the quality of life for these patients in France.

At a glance

Status

Recruiting

Sponsor

Centre Hospitalier St Anne

Enrolment target

Start

13 Jun 2025

Estimated completion

12 Dec 2025

Quality of Life Meningioma

What is this study about?

Meningiomas are a common type of brain tumour. Even though they are often slow-growing and sometimes don't need immediate treatment, they can still significantly affect a person's life. This might include how they feel emotionally, their social interactions, or their general well-being. However, doctors often don't have a clear way to measure how much these tumours impact a patient's quality of life, especially in French-speaking countries.

There's a special questionnaire called MQOL (Meningioma Quality of Life) that helps understand these challenges. It asks questions about different aspects of daily life, helping to paint a full picture of how the condition affects someone. The problem is, this important tool isn't currently available in French, meaning that French-speaking patients and doctors can't fully benefit from it.

This study aims to fix this. It's a two-step project. First, medical experts will carefully translate the MQOL questionnaire into French, making sure the meaning stays the same and it sounds natural. Second, they will test this new French version with 50 patients who have meningiomas. By comparing answers from other well-known health questionnaires, they will check if the French MQOL is accurate and reliable. This will allow healthcare professionals to better understand and support French-speaking patients with meningiomas.

Key takeaways

The study is translating a brain tumour questionnaire into French.
It aims to better understand daily life for meningioma patients.
No new treatments or medicines are involved.
Participation means completing questionnaires.
It's for adults 18+ with a meningioma diagnosis.
You must understand and speak French well.

Who may be eligible?

To be considered for this study, you need to be an adult, aged 18 or older. You must also have been diagnosed with an intracranial meningioma, which means a meningioma located inside the skull. This diagnosis should have been confirmed by medical scans or an operation.

There are also some reasons why you wouldn't be able to join. For example, if you are pregnant or breastfeeding, you cannot take part. Also, if you are currently in prison or similar situations, or receiving mental health care that restricts your freedom, you wouldn't be able to participate.

It's important that you can understand and speak French well enough to complete the questionnaire. Finally, you must willingly agree to take part; no one can be forced into the study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been diagnosed with a meningioma in your head?
Do you speak and understand French well?
Are you able to agree to join the study voluntarily?
Are you currently pregnant or breastfeeding? (If yes, you cannot join.)

Answer every question to see your result.

What does participation involve?

This study primarily involves completing questionnaires. There are no medications or special procedures involved. You will be asked to complete the newly translated MQOL questionnaire in French, along with a few other established health questionnaires (like EQ-5D, Karnofsky, and FACT-Br) that help measure your quality of life and general health. The study won't involve any hospital visits beyond what you would usually have for your condition. The total duration of your participation would involve completing these questionnaires, likely at a single point in time, and there will be no ongoing follow-up specifically for the study itself.

Potential risks and benefits

A potential benefit of taking part is contributing to a better understanding of how meningiomas affect quality of life for French-speaking patients, which could lead to improved patient care in the future. The risks are very low; you might find some questions sensitive, but you are not obliged to answer any question you don't feel comfortable with. There are no physical risks involved. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

GHU Paris -Psychiatrie & Neurosciences
Verified postcode
Paris, France· Recruiting

Common questions

What is a meningioma?

A meningioma is a type of tumour that grows from the membranes (meninges) that surround the brain and spinal cord. They are often not cancerous, but can still cause problems.

What does 'quality of life' mean in this study?

It means how your meningioma affects your daily well-being, including your physical comfort, emotions, social activities, and overall happiness.

Do I need to live in France to participate?

While the questionnaire is being translated into French, the study description doesn't specifically state a geographical requirement beyond being fluent in French. You would need to discuss this with the study team.

Will I take any new medicine if I join?

No, this study does not involve any new medicines or treatments. It is purely about completing questionnaires.

How long will my involvement in the study last?

Your involvement will likely be a one-off completion of questionnaires. The study description does not mention any long-term follow-up for participants.

How to find out more

Viviane AWASSI

v.awassi@ghu-paris.fr 01.45.65.84.86 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.